{
  "pmcid": "8765334",
  "sha256": "7dcada3a77f15abc79c443ae4fce283e54295604021cd045c50593c7a221bea5",
  "timestamp_utc": "2025-11-10T00:10:41.392378+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.19496525096525,
    "reading_ease": 31.215124839124854,
    "word_count": 259
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Stockholm III Trial: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This multicenter, randomized controlled trial included 840 patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "840 patients with biopsy-proven resectable rectal adenocarcinoma"
      },
      "Intervention": {
        "score": 2,
        "evidence": "comparing short-course radiotherapy (SRT) with immediate surgery, SRT with delayed surgery, and long-course radiotherapy (LRT) with delayed surgery"
      },
      "Objective": {
        "score": 1,
        "evidence": "The Stockholm III trial assessed the long-term oncological outcomes and health-related quality of life (HRQoL)"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was time to local recurrence (LR) over a minimum follow-up of 5 years"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomization was stratified by center"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applicable"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "357, 355, and 128 patients were randomized to SRT, SRT-delay, and LRT-delay, respectively"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "analysis was conducted on an intention-to-treat basis"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The incidence of LR was 3/129, 4/128, and 7/128, and distant metastases (DM) were 31/129, 38/128, and 38/128"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were not significantly different among groups"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered under NTC00904813"
      },
      "Funding": {
        "score": 1,
        "evidence": "funded by the Swedish Research Council, Swedish Cancer Society, Stockholm Cancer Society, and other Swedish institutions"
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}